Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NCT ID: NCT05626530

Last Updated: 2025-04-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-02
• Study Completion Date: 2025-12-15

Brief Summary

This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.

This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.

Detailed Description

This study will enroll solid organ transplant recipients who develop cytomegalovirus infection and disease who have been treated. At the time of finishing treatment, if the clinician feels that secondary prophylaxis is indicated, they will be enrolled to receive Letermovir 480 mg orally once a day for 60 days. CMV specific T cell assays will be obtained at the initiation of secondary prophylaxis and at the discontinuation of secondary prophylaxis. Patients will be followed for 4 months following discontinuation of secondary prophylaxis to see if they relapse.

Conditions

Cytomegalovirus Infections; Infection in Solid Organ Transplant Recipients; Neutropenia; Antiviral Toxicity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

single arm

This is an open label single arm study

Group Type: OTHER

Letermovir

Intervention Type: DRUG

Open label 480 mg given daily for 60 days

Interventions

Letermovir

Open label 480 mg given daily for 60 days

Intervention Type: DRUG

Other Intervention Names

Active drug

Eligibility Criteria

Inclusion Criteria

1. Adult (> 18 years old) solid organ transplant recipients (heart, kidney or liver patients) recovering from treated CMV disease in whom the clinician deems that the patient need secondary prophylaxis and in whom written informed consent is obtained.

2. Patient able to participate with follow up for 6 months

3. Not enrolled in competing clinical trials

Exclusion Criteria

1. Patients with creatinine clearance less than 10 ml per min at time of enrollment

2. Hypersensitivity to letermovir or has a CMV isolate which is known to be resistant to letermovir based on prior testing

3. On CVVH or renal dialysis at the time of enrollment

4. Has Child Pugh Class C severe hepatic insufficiency at screening.

5. Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency at screening.

Note: Moderate hepatic insufficiency is defined as Child Pugh Class B (Appendix 8); moderate to severe renal insufficiency is defined as CrCl <50 mL/min, as calculated by the Cockcroft-Gault equation.

6. Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy.

7. Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 90 days following cessation of study therapy.

8. Is expecting to donate eggs or sperm starting from the time of consent through at least 90 days following cessation of study therapy.

9. Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study.

10. Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the 6 months) of drug or alcohol abuse or dependence.

Note: Participants with a history of marijuana use which is not deemed excessive by an investigator or does not interfere with the participant's daily function may participate in the study.

11. Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5× half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Participants previously treated with an investigational monoclonal antibody will be eligible to participate after a 150-day washout period.

12. Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent that is not approved or is planning to participate in a study of a CMV vaccine or another unapproved CMV investigational agent during the course of this study.

-

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tufts Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jennifer K Chow, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Tufts Medical Center

Locations

Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases

Boston, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Jennifer K Chow, MD, MS

Role: CONTACT

Jennifer.Chow@TuftsMedicine.org

617-636-5244

Whitney K Perry, MD, MS

Role: CONTACT

Whitney.Perry@tuftsMedicine.org

339-368-0047

Facility Contacts

Jennifer K Chow, MD, MS

Role: primary

Jennifer.Chow@TuftsMedicine.org

617-636-5244

Whitney Perry, MD, MS

Role: backup

Whitney.Perry@tuftsMedicine.org

339-368-0047

Other Identifiers

00003219

Identifier Type: -

Identifier Source: org_study_id